Ainos, Inc. — Form 8-K Summary
Reporting context: The report covers a material agreement entered into on September 24, 2026, and announced September 28, 2026. Ainos granted BioPhoenix Co., Ltd. a global exclusive license to its VELDONA low-dose oral interferon alpha technology for Sjögren’s Disease and thrombocytopenia.
Financial and commercial terms
- BioPhoenix owes a $600,000 upfront license fee, payable after it receives the complete data package and written confirmation that technology transfer is complete.
- Ainos is also entitled to a one-time fee upon BioPhoenix’s first sublicense and 25% of BioPhoenix’s net sublicensing revenue for the licensed indications.
- If BioPhoenix licenses all additional VELDONA indications made available under the agreement, total license fees—including the upfront and first-sublicense fees—would be approximately $10.0 million. This is conditional, not a guaranteed payment.
- The filing provides no financial-statement results, cash flow, margins, debt, liquidity figures, or quantified revenue recognition from the agreement.
Material terms and changes
- The license is exclusive, worldwide, irrevocable, transferable, and sublicensable, covering research, development, manufacturing, and commercialization for the specified indications.
- During the agreement and for 10 years after it ends, Ainos may not compete anywhere in the world in those indications.
- BioPhoenix has a right of first refusal and call option for certain additional VELDONA indications that reach Phase 2, plus an option to license other non-licensed indications under separate agreements.
- The agreement runs by indication and country until the later of the last applicable patent expiration or 20 years after the effective date, unless terminated earlier. Either party may terminate for the other’s uncured material breach or insolvency.
Outlook, risks, and unusual items
The filing gives no operating guidance or forecast. Potential proceeds depend on completion of data and technology transfer, a first sublicense, and BioPhoenix’s exercise of additional licensing options. The global exclusivity and extended non-compete restriction may limit Ainos’s ability to pursue these indications independently. The agreement includes customary representations, warranties, covenants, indemnification, and confidentiality provisions. Portions of the filed agreement and its attachments were omitted or redacted.
Important facts for investors to verify
- Whether and when the data package and technology transfer conditions are completed and the $600,000 fee becomes payable.
- Whether BioPhoenix grants a sublicense, triggering the one-time fee and potential 25% share of net sublicensing revenue.
- Whether BioPhoenix exercises additional-indication options and the specific fees and terms that apply.
- The detailed terms in Exhibit 10.1, including redacted provisions and omitted schedules, and any subsequent updates on performance or termination.